• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2
Elecsys IGRA SARS-CoV-2 testsupports the better understanding of immuneresponse to SARS-CoV-2 infection or vaccinationThe test detects T-cell response, which may play an important role in determining if immune protection has been achievedThenew diagnostic testmayprovide clinical care guidance, particularly forimmunocompromised and high-risk patient groupsBasel, 15 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® IGRA SARS-CoV-2 test in countries that accept the CE Mark1. The Elecsys IGRA SARS-CoV-2 test supports the better understanding of immune response to SARS-CoV-2 infection...
Source: Roche Investor Update - August 15, 2022 Category: Pharmaceuticals Source Type: news

Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab
The novel coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2, an enveloped nonsegmented positive-sense RNA β-coronavirus. The virus can trigger a cascade of biological events that can lead to critical illness. It is urgent to gain an in-depth understanding of the critical activators that foreshadow patients at highest risk for mortality.1 Patients who have received tocilizumab for COVID-19–related cyt okine storm have had improvements in C-reactive protein (CRP), lymphocytosis, and chest computed tomography findings.
Source: Annals of Allergy, Asthma and Immunology - December 29, 2020 Category: Allergy & Immunology Authors: Nicholas L. Hartog, Alan T. Davis, Jeremy W. Prokop, Andrew Walls, Surender Rajasekaran Tags: Letters Source Type: research

Monitoring Neutrophil to Lymphocyte Ratio in COVID-19 Patients Receiving Tocilizumab
The novel coronavirus disease (COVID-19) is an infectious disease caused by SARS-CoV-2, an enveloped non-segmented positive-sense RNA β-coronavirus. The virus can trigger a cascade of biological events that can lead to critical illness. It is urgent to gain an in-depth understanding of the critical activators that foreshadow patients highest risk for mortality.(1) Patients who have received tocilizumab for COVID-19 related cytoki ne storm have had improvements in c-reactive protein (CRP), lymphocytosis, and chest CT findings.(2) There exist a lack of understanding on which patients would benefit from Tocilizumab administration.
Source: Annals of Allergy, Asthma and Immunology - December 29, 2020 Category: Allergy & Immunology Authors: Nicholas L. Hartog, Alan T. Davis, Jeremy W. Prokop, Andrew Walls, Surender Rajasekaran Tags: Letters Source Type: research